BioUtah, the state's trade association for the life sciences industry, has opened early bird registration for the 2026 Utah Life Sciences Summit (ULSS), presented by Mayer Brown. The summit is scheduled for November 11 at the Hilton Salt Lake City Center. Early bird pricing is available until October 11, providing a limited window for potential attendees to secure reduced rates. The full announcement, including downloadable images and bios, can be accessed by click here.
The early bird discount is significant because it lowers the cost of participation for a premier gathering that brings together professionals from across Utah's life sciences sector. With the industry encompassing medical device manufacturing, biotechnology, biopharmaceuticals, diagnostics, and research services, the summit serves as a critical venue for networking, knowledge exchange, and collaboration. By offering a price incentive, BioUtah aims to maximize attendance and ensure broad representation from companies of all sizes, from startups to established firms.
A major draw of the 2026 summit is the keynote speaker, Dr. Michelle Tarver, Director of the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration. Dr. Tarver will host an in-person Town Hall discussion, giving attendees a rare opportunity to engage directly with a top regulatory official. This interaction is particularly important for medical device and diagnostics companies in Utah, as FDA policies and approvals directly impact their product development and market access. The Town Hall format suggests a candid dialogue on current regulatory priorities, potentially covering topics such as digital health, AI in medical devices, and post-market surveillance.
Beyond the keynote, the summit will feature topic-specific tracks designed to address pressing issues in the life sciences. These tracks include workforce development, regulatory affairs, legal considerations, and artificial intelligence. Each track reflects a critical area for industry growth and resilience. The workforce track, for example, may tackle talent acquisition and retention challenges in a competitive market. The regulatory track could delve into evolving compliance requirements, while the legal track might explore intellectual property and liability issues. The AI track is especially timely, as artificial intelligence continues to revolutionize drug discovery, diagnostics, and patient care, raising questions about validation, ethics, and integration.
Utah's life sciences community is a key economic driver, and the summit's focus on these forward-looking themes underscores the state's ambition to remain at the forefront of innovation. BioUtah, as an independent 501(c)(6) trade association, plays a central role in advocating for and connecting its member companies. More information about the organization is available at BioUtah.
The early bird deadline of October 11 creates a sense of urgency for interested parties. After that date, registration fees will increase, potentially limiting access for some smaller companies or individual researchers. The summit's timing in November also allows attendees to plan ahead and budget for the event. With the combination of a high-profile FDA keynote, practical breakout sessions, and networking opportunities, the 2026 ULSS is positioned to be a pivotal event for Utah's life sciences ecosystem. Those who register early not only save money but also secure their place at what promises to be a sold-out gathering.


